| pubmed-article:11665979 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11665979 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:11665979 | lifeskim:mentions | umls-concept:C0151449 | lld:lifeskim |
| pubmed-article:11665979 | lifeskim:mentions | umls-concept:C0666743 | lld:lifeskim |
| pubmed-article:11665979 | lifeskim:mentions | umls-concept:C0031928 | lld:lifeskim |
| pubmed-article:11665979 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:11665979 | pubmed:dateCreated | 2001-10-22 | lld:pubmed |
| pubmed-article:11665979 | pubmed:abstractText | Tumor necrosis factor alpha (TNFalpha) is a proinflammatory cytokine involved in the pathogenesis of Sjögren's syndrome (SS), and blockade of TNFalpha may reduce the activity of the disease. The purpose of this study was to evaluate the safety and potential efficacy of infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody, in patients with active primary SS. | lld:pubmed |
| pubmed-article:11665979 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11665979 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11665979 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11665979 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:11665979 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11665979 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11665979 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11665979 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11665979 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:11665979 | pubmed:issn | 0004-3591 | lld:pubmed |
| pubmed-article:11665979 | pubmed:author | pubmed-author:AppelboomTT | lld:pubmed |
| pubmed-article:11665979 | pubmed:author | pubmed-author:KissRR | lld:pubmed |
| pubmed-article:11665979 | pubmed:author | pubmed-author:SalmonII | lld:pubmed |
| pubmed-article:11665979 | pubmed:author | pubmed-author:DemolsPP | lld:pubmed |
| pubmed-article:11665979 | pubmed:author | pubmed-author:SteinfeldS... | lld:pubmed |
| pubmed-article:11665979 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11665979 | pubmed:volume | 44 | lld:pubmed |
| pubmed-article:11665979 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11665979 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11665979 | pubmed:pagination | 2371-5 | lld:pubmed |
| pubmed-article:11665979 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11665979 | pubmed:meshHeading | pubmed-meshheading:11665979... | lld:pubmed |
| pubmed-article:11665979 | pubmed:meshHeading | pubmed-meshheading:11665979... | lld:pubmed |
| pubmed-article:11665979 | pubmed:meshHeading | pubmed-meshheading:11665979... | lld:pubmed |
| pubmed-article:11665979 | pubmed:meshHeading | pubmed-meshheading:11665979... | lld:pubmed |
| pubmed-article:11665979 | pubmed:meshHeading | pubmed-meshheading:11665979... | lld:pubmed |
| pubmed-article:11665979 | pubmed:meshHeading | pubmed-meshheading:11665979... | lld:pubmed |
| pubmed-article:11665979 | pubmed:meshHeading | pubmed-meshheading:11665979... | lld:pubmed |
| pubmed-article:11665979 | pubmed:meshHeading | pubmed-meshheading:11665979... | lld:pubmed |
| pubmed-article:11665979 | pubmed:meshHeading | pubmed-meshheading:11665979... | lld:pubmed |
| pubmed-article:11665979 | pubmed:meshHeading | pubmed-meshheading:11665979... | lld:pubmed |
| pubmed-article:11665979 | pubmed:meshHeading | pubmed-meshheading:11665979... | lld:pubmed |
| pubmed-article:11665979 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11665979 | pubmed:articleTitle | Infliximab in patients with primary Sjögren's syndrome: a pilot study. | lld:pubmed |
| pubmed-article:11665979 | pubmed:affiliation | Department of Rheumatology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium. ssteinfe@ulb.ac.be | lld:pubmed |
| pubmed-article:11665979 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11665979 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11665979 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11665979 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11665979 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11665979 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11665979 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11665979 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11665979 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11665979 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11665979 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11665979 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11665979 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11665979 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11665979 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11665979 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11665979 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11665979 | lld:pubmed |
